Skip to main content
SpringerLink
Log in

The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Single nucleotide polymorphisms (SNPs) in UGT2B7 C802T and CYP3A4*1G impact drug metabolism. This study aimed to investigate the impact of these SNPs on the efficacy of oxycontin for pain relief in cancer patients.

Methods

A total of 57 Han Chinese cancer patients (age range 20–70 years) who received oxycontin to ease pain for the first time were enrolled and divided into two groups (refractory group and remission group) according to pain relief. Peripheral blood samples were collected from each patient for sequencing analysis. The genotype and allele frequency between the two groups were analyzed using the chi-square test.

Results

The T allele frequency of UGT2B7 C802T was 25% among all participants, but was higher (32%) in the refractory group (P = 0.047). The variant allele frequency of CYP3A4*1G was 27% and did not differ between the refractory group and remission group.

Conclusion

The palliative effect of oxycontin is better in patients with UGT2B7 802CC than in those with 802TT. CYP3A4*1G SNP is unlikely to affect pain relief efficacy of oxycontin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shi Q, Cleeland CS, Klepstad P, Miaskowski C, Pedersen NL (2010) Biological pathways and genetic variables involved in pain. Qual Life Res 19:1407–1417

    Article  PubMed  Google Scholar 

  2. Maeda K, Sugiyama Y (2008) Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 23:223–235

    Article  PubMed  CAS  Google Scholar 

  3. King CD, Rios GR, Green MD, Tephly TR (2000) UDP-glucuronosyltransferases. Curr Drug Metab 1:143–161

    Article  PubMed  CAS  Google Scholar 

  4. Coffman BL, Rios GR, King CD, Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1–4

    PubMed  CAS  Google Scholar 

  5. Yoo HD, Lee YB (2011) Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. Arch Pharm Res 34:1817–1828

    Article  PubMed  CAS  Google Scholar 

  6. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT (2011) Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Clin Drug Investig 31:143–153

    Article  PubMed  CAS  Google Scholar 

  7. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto YI, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada JI (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100

    Article  PubMed  Google Scholar 

  8. Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89:2027–2030

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Somogyi AA, Barratt DT, Coller JK (2007) Pharmacogenetics of opioids. Clin Pharmacol Ther 81:429–444

    Article  PubMed  CAS  Google Scholar 

  10. Campa D, Gioia A, Tomei A, Poli P, Barale R (2008) Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83:559–566

    Article  PubMed  CAS  Google Scholar 

  11. Fujita K, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, Araki K, Kodama K, Nagashima F, Ichikawa W, Narabayashi M, Akiyama Y, Kawara K, Shiomi M, Ogata H, Iwasa H, Okazaki Y, Hirose T, Sasaki Y (2010) Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol 65:251–258

    Article  PubMed  CAS  Google Scholar 

  12. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79:461–479

    Article  PubMed  CAS  Google Scholar 

  13. Kummer O, Hammann F, Moser C, Schaller O, Drewe J, Krahenbuhl S (2011a) Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 67:63–71

    Article  PubMed  CAS  Google Scholar 

  14. Zhang W, Chang YZ, Kan QC, Zhang LR, Li ZS, Lu H, Wang ZY, Chu QJ, Zhang J (2010) CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol 66:61–66

    Article  PubMed  CAS  Google Scholar 

  15. Du J, Zhang A, Wang L, Xuan J, Yu L, Che R et al (2010) Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 24:1115–1120

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by the grant of the new technology and business of Tongji Hospital.

Author information

Author notes

  1. Jingwen Li and Peng Peng contributed equally to this work.

Authors and Affiliations

  1. Department of Oncology, Xiangyang Center Hospital, Affiliated Hospital of Hubei University of Arts and Science, Jingzhou Street 39, Xiangyang, 441021, China

    Jingwen Li

  2. Department of Neurosurgery, Xiangyang Center Hospital, Affiliated Hospital of Hubei University of Arts and Science, Jingzhou Street 39, Xiangyang, 441021, China

    Peng Peng

  3. Department of Oncology, TongJi Hospital, TongJi Medical College, HuaZhong University of Science and Technology, Jiefang Avenue 1095, Wuhan, 430030, China

    Qi Mei, Shu Xia, Yijun Tian, Liya Hu & Yuan Chen

Authors
  1. Jingwen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peng Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shu Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yijun Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liya Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuan Chen.

Ethics declarations

The study was approved by the Ethical Committee of Tongji Hospital. All written informed consent documents were obtained from each participant before the study.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, J., Peng, P., Mei, Q. et al. The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin. Support Care Cancer 26, 2763–2767 (2018). https://doi.org/10.1007/s00520-018-4130-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-018-4130-4

Keywords

Search

Navigation